Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Abbott Profit Falls 14% on Charges

April 20, 2011 7:25 am | News | Comments

Drug and medical device maker Abbott Laboratories said its first-quarter net income fell 14 percent on restructuring and acquisition costs and other expenses. For the period ended March 31, the company earned $864 million, or 55 cents per share.


Decoding Genes with the Help of Open-Source Encyclopedia

April 20, 2011 7:22 am | News | Comments

A massive database cataloging the human genome's functional elements—including genes, RNA transcripts, and other products—is being made available as an open resource to the scientific community, classrooms, science writers, and the public.


New Study Shows High Incidence of Virological Failure

April 20, 2011 7:17 am | News | Comments

A study of European HIV-positive children shows that 12% of children (around 1 in 8) develop triple-class virological failure by 5 years after starting their antiretroviral drug treatment program.


Targeting IL-6 to Halt Breast, Prostate Cancer

April 20, 2011 7:14 am | News | Comments

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.


Using Stress To Detonate Cancer Cells

April 20, 2011 6:59 am | News | Comments

Researchers have found a new way to force cancer cells to self-destruct. Low doses of an anti-cancer drug currently in development sensitizes tumor cells to a second drug, called TRAIL, also being developed as a cancer treatment.


Biosensor Microchip Could Speed Up Drug Development

April 20, 2011 6:52 am | News | Comments

Stanford researchers have developed a new biosensor microchip that could significantly speed up the process of drug development. The microchips, packed with highly sensitive "nanosensors," analyze how proteins bind to one another.


GST Protein Purification

April 19, 2011 8:08 am | Product Releases | Comments

G-Biosciences offers a unique product for the purification of protein from bacterial samples. Our HOOK GST Protein Purification kits allow for the rapid extraction of soluble, GST tagged protein.


Automated Cell Culture

April 19, 2011 8:06 am | Drug Discovery & Development | Product Releases | Comments

TAP Biosystems is introducing three new options for their CompacT SelecT automated cell culture systems that will enable scientists to automate processing of T75 flasks, pipette chilled reagents at low volumes, and optimize oxygen levels.


SciClone Buys NovaMed for $52M

April 19, 2011 7:59 am | News | Comments

SciClone Pharmaceuticals, Inc. announced that it has acquired China-based NovaMed Pharmaceuticals Inc. The acquisition brings additional broad sales and marketing to its growing and profitable China focused specialty pharmaceutical business.


DCR Adds Clean Room for USP 797 Compliance

April 19, 2011 7:52 am | News | Comments

DaVita Clinical Research, a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, announces the completion of its Phase 1-2a Clean Room to comply with USP 797 high risk regulations.


Anti-depressants Boost Brain Cells After Injury

April 19, 2011 7:44 am | News | Comments

A new study was begun after neurosurgeons noticed that patients with brain injuries who had been prescribed anti-depressants were doing better in unexpected ways than their counterparts who were not taking such medications.


Injection Could Limit Heart Attack-Stroke Damage

April 19, 2011 7:40 am | News | Comments

Medical researchers held out promise that a simple injection is being developed to limit the devastating consequences of heart attacks and strokes. Work has already begun to translate the research into novel clinical therapies.


Phase 2 BC-3781 Trial Complete

April 19, 2011 7:34 am | News | Comments

Nabriva Therapeutics announced the successful results of a Phase 2 clinical trial of BC-3781 in acute bacterial skin and skin structure infections. BC-3781 is the first of a new class of systemically available pleuromutilin antibiotics.


Amarin's ANCHOR Trial Successful

April 19, 2011 7:27 am | News | Comments

Amarin Corporation plc reported positive top-line results from its ANCHOR trial for the Company’s lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.


Lilly to Meet Cost-Cutting Goals

April 19, 2011 7:12 am | News | Comments

Eli Lilly and Co. is poised to meet or exceed its goals of cutting annual costs by $1 billion and eliminating 5,500 jobs, Chief Financial Officer Derica Rice said following the drugmaker's first-quarter earnings report.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.